1h Free Analyst Time
The darier disease drugs market is forecasted to grow by USD 44.3 million during 2023-2028, accelerating at a CAGR of 4.49% during the forecast period. The report on the darier disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increase in demand for advanced dermatological diagnosis, launch of new darier disease drugs, and need for safe and stable drugs that require minimal monitoring.
The darier disease drugs market is segmented as below:
By Product
- Topical retinoids
- Oral retinoids
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the darier disease drugs market covers the following areas:
- Darier disease drugs market sizing
- Darier disease drugs market forecast
- Darier disease drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
360 degree market analysis
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global darier disease drugs market: AbbVie Inc., Amneal Pharmaceuticals Inc., Bausch Lomb Corp., BridgeBio Pharma Inc, Galderma SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson and Johnson Services Inc., Laminar Pharma, Mayne Pharma Group Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sawai Group Holdings Co. Ltd., Sigmapharm Laboratories LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Tolmar Pharmaceuticals Inc., and Validus Pharmaceuticals LLC.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing research on gene therapy."
According to the report, one of the major drivers for this market is the increase in demand for advanced dermatological diagnosis.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Amneal Pharmaceuticals Inc.
- Bausch Lomb Corp.
- BridgeBio Pharma Inc
- Galderma SA
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- Johnson and Johnson Services Inc.
- Laminar Pharma
- Mayne Pharma Group Ltd.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sawai Group Holdings Co. Ltd.
- Sigmapharm Laboratories LLC
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Tolmar Pharmaceuticals Inc.
- Validus Pharmaceuticals LLC